SecSonar.com

CG Oncology, Inc. Common stock (CGON)

CG Oncology, Inc. Common stock at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

CG Oncology, Inc. Common stock (CGON) is a Biotechnology company based in US with a market capitalization of $5.4B. Revenue grew 254.7% year-over-year and free cash flow was negative at -$132.5M. This page tracks CGON's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 113 employees · IPO Jan 25, 2024

Valuation

Valuation & price

$66.93 · as of May 17, 2026 · -9.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.20

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$73.43$48.69$23.95Jul 25Dec 25Jul 26Jul 7, 25$26.25Jul 9, 25$27.04Jul 11, 25$26.72Jul 15, 25$24.95Jul 17, 25$28.46Jul 21, 25$26.90Jul 23, 25$26.32Jul 25, 25$26.10Jul 29, 25$26.04Jul 31, 25$26.69Aug 4, 25$26.09Aug 6, 25$25.29Aug 11, 25$23.95Aug 13, 25$26.49Aug 15, 25$25.70Aug 19, 25$25.56Aug 21, 25$25.98Aug 25, 25$25.42Aug 27, 25$26.48Aug 29, 25$26.82Sep 3, 25$28.67Sep 5, 25$33.07Sep 9, 25$33.47Sep 11, 25$33.16Sep 16, 25$35.76Sep 18, 25$38.82Sep 22, 25$37.04Sep 24, 25$36.68Sep 26, 25$37.54Sep 30, 25$40.28Oct 2, 25$39.85Oct 6, 25$38.13Oct 8, 25$40.71Oct 10, 25$43.25Oct 14, 25$42.85Oct 16, 25$41.85Oct 21, 25$43.06Oct 23, 25$41.98Oct 27, 25$44.29Oct 29, 25$42.98Oct 31, 25$43.27Nov 4, 25$39.07Nov 6, 25$39.69Nov 10, 25$40.22Nov 12, 25$39.41Nov 14, 25$41.01Nov 18, 25$42.55Nov 20, 25$40.71Nov 25, 25$45.51Nov 28, 25$44.84Dec 2, 25$41.37Dec 4, 25$44.73Dec 8, 25$42.80Dec 10, 25$41.74Dec 12, 25$40.94Dec 16, 25$37.85Dec 18, 25$38.00Dec 22, 25$40.08Dec 24, 25$40.14Dec 29, 25$39.86Jan 2, 26$41.79Jan 6, 26$40.37Jan 8, 26$41.93Jan 12, 26$53.72Jan 14, 26$55.51Jan 16, 26$54.73Jan 21, 26$57.13Jan 23, 26$53.81Jan 27, 26$55.10Jan 29, 26$53.42Feb 2, 26$54.34Feb 4, 26$51.98Feb 9, 26$51.08Feb 11, 26$53.55Feb 13, 26$51.50Feb 18, 26$55.21Feb 20, 26$57.63Feb 24, 26$58.34Feb 26, 26$56.11Mar 2, 26$57.76Mar 4, 26$61.57Mar 6, 26$61.88Mar 10, 26$62.80Mar 12, 26$62.97Mar 17, 26$68.64Mar 19, 26$65.86Mar 23, 26$64.96Mar 25, 26$65.81Mar 27, 26$64.62Mar 31, 26$67.68Apr 2, 26$67.48Apr 7, 26$69.81Apr 9, 26$68.56Apr 13, 26$67.70Apr 15, 26$67.68Apr 17, 26$73.43Apr 22, 26$69.88Apr 24, 26$68.68Apr 28, 26$65.55Apr 30, 26$66.74May 4, 26$67.70May 6, 26$68.01May 8, 26$69.62May 12, 26$72.07May 14, 26$69.54May 18, 26$62.93May 20, 26$64.76May 22, 26$64.25May 28, 26$60.73Jun 1, 26$59.23Jun 3, 26$54.42Jun 5, 26$53.72Jun 9, 26$56.67Jun 11, 26$57.64Jun 15, 26$59.55Jun 17, 26$60.43Jun 22, 26$66.25Jun 24, 26$68.72Jun 26, 26$71.96Jul 2, 26$70.36
$23.9552-week range$74.00
Loading valuation history…

Fundamentals

Key fundamentals

$5.4B

Market cap

254.7%

Revenue growth (YoY)

-15.0%

Gross margin

-$132.5M

Free cash flow (USD)

-$735.1M

Net debt

Net cash position

23.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2021 → 2025

FY 2021$10.4MFY 2022$191.0KFY 2023$204.0KFY 2024$1.1MFY 2025$4.0M
$10.4M$4M

Free cash flow by year

2021 → 2025

FY 2021$-13.8MFY 2022$-29.8MFY 2023$-45.7MFY 2024$-78.9MFY 2025$-132.5M
-$13.8M-$132.5M

Gross margin by year

2021 → 2025

FY 202199.9%FY 202292.2%FY 2023100.0%FY 2024100.0%FY 2025-15.0%
99.9%-15.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider buyInsider Buy $24.8MLiu Brian Guan-Chyun · Director · $24.8MJun 29, 2026Filing
  • Insider sellInsider Sell $350K · 10b5-1 PlanPOST LEONARD E · Director · $350KJun 25, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 8, 2026Filing
  • 8-K eventExecutive Departure and AppointmentMay 26, 2026Filing
  • 8-K eventEarnings ReleaseMay 8, 2026Filing
  • Quarterly report10-Q FiledMay 8, 2026Filing
  • 8-K eventCFO AppointmentApr 13, 2026Filing

Questions

Frequently asked questions

What is CG Oncology, Inc. Common stock's market cap?

CG Oncology, Inc. Common stock (CGON) has a market capitalization of $5.4B.

What is CGON's P/E ratio?

A meaningful P/E ratio is not available for CGON — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CGON's price-to-book (P/B) ratio?

CGON trades at 7.20 times book value per share.

Are insiders buying CGON stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 1 sell at CG Oncology, Inc. Common stock in the last 90 days.

Same arena

Related companies in Biotechnology

CRSP

CRISPR Therapeutics AG

$5.4B

LQDA

Liquidia Corporation

$5.5B

MIRM

Mirum Pharmaceuticals, Inc.

$5.1B

LEGN

Legend Biotech Corporation

$5B

TGTX

TG Therapeutics, Inc.

$5.9B

PTCT

PTC Therapeutics, Inc.

$6.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.